Euphol

Euphol is a tetracyclic triterpene alcohol isolated primarily from Euphorbia tirucalli latex that exerts anti-inflammatory and anticancer effects by modulating phospholipase A2 activity and suppressing NF-κB-driven pro-inflammatory signaling. Research in animal and cell models suggests it may inhibit tumor cell proliferation and reduce inflammatory mediator release, though human clinical trials have not yet been conducted.

Origin & History

Euphol is a tetracyclic triterpene alcohol primarily extracted from the latex sap of the *Euphorbia tirucalli* plant, a succulent shrub native to tropical regions like Brazil. It belongs to the eupholane-type tetracyclic triterpenes and is isolated as the main constituent from this plant's latex.

Historical & Cultural Context

In Brazilian folk medicine, the latex sap of *Euphorbia tirucalli*, which contains euphol, has been traditionally used for treating various cancers such as leukemia, prostate, and breast cancers. No specific duration or other traditional systems were detailed.

Health Benefits

• May reduce inflammation in colitis models by decreasing pro-inflammatory mediators and increasing IL-10 (animal model evidence).
• Shows cytotoxic effects against various cancer cell lines, particularly pancreatic and esophageal squamous cells (in vitro evidence).
• Inhibits proliferation, motility, and colony formation in cancer cells, and synergizes with chemotherapeutic agents like gemcitabine and paclitaxel (in vitro evidence).
• Induces apoptosis and autophagy-associated cell death in glioma cells (in vitro evidence).
• Modulates key signaling pathways such as MAP Kinase/ERK1/2 and PI3K/AKT in cancer cells (in vitro evidence).

How It Works

Euphol inhibits phospholipase A2 (PLA2), an enzyme responsible for releasing arachidonic acid from membrane phospholipids, thereby reducing downstream synthesis of prostaglandins and leukotrienes that drive inflammation. In cancer models, euphol activates caspase-dependent apoptotic pathways and disrupts cell cycle progression at the G1/S checkpoint by modulating cyclin D1 and CDK4 expression. It also upregulates the anti-inflammatory cytokine IL-10 while suppressing TNF-α and IL-6 production, likely through NF-κB pathway inhibition.

Scientific Research

No human clinical trials or meta-analyses were identified; all evidence is limited to preclinical studies in animal models and cell lines. Research has focused on its effects in mouse models of colitis and various cancer cell lines.

Clinical Summary

All current evidence for euphol derives from in vitro cell culture studies and rodent animal models, with no published human clinical trials to date. In murine colitis models, oral administration of euphol reduced myeloperoxidase activity and histological damage scores while elevating colonic IL-10 levels. Cytotoxicity studies report IC50 values in the low micromolar range (approximately 5–20 µM) against pancreatic adenocarcinoma and esophageal squamous cell carcinoma lines. The evidence base is considered preliminary, and translation to human therapeutic doses and safety profiles remains unestablished.

Nutritional Profile

Euphol is not a nutrient or food substance; it is a tetracyclic triterpene alcohol (C30H50O, MW ~426.7 g/mol) isolated primarily from the latex of Euphorbia tirucalli (pencil cactus/firestick plant) and related Euphorbia species. It has no conventional nutritional profile (no macronutrients, vitamins, minerals, fiber, or protein content). Key bioactive characteristics: • Chemical class: Tirucallane-type tetracyclic triterpenoid (specifically, tirucall-8,24-dien-3β-ol). • Typical concentrations in E. tirucalli latex: approximately 22–48 mg/g of crude dried latex, though this varies with geographic origin, season, and extraction method. • Closely related isomer: Tirucallol (the 3α-epimer); euphol is the 3β-hydroxy form. • Bioavailability notes: As a lipophilic triterpenoid (logP ~8–9), euphol has poor aqueous solubility, which limits oral bioavailability. In animal pharmacokinetic studies, absorption is enhanced by lipid-based delivery vehicles or nanoemulsion formulations. First-pass hepatic metabolism likely reduces systemic availability. No human pharmacokinetic data are currently published. • Other co-occurring bioactive compounds in the E. tirucalli latex matrix include: euphorbol (another triterpene), cycloartenol, lupeol, β-sitosterol, ingenol esters, and various diterpene esters (phorbol-type), some of which are irritant/co-carcinogenic and must be separated from euphol during purification. • Euphol itself is studied as an isolated compound at pharmacological doses (typically 10–100 mg/kg in rodent models; 1–50 µM in in vitro assays) and is not consumed as part of a normal human diet.

Preparation & Dosage

Clinically studied dosages are absent; preclinical data report oral administration of 3, 10, or 30 mg/kg in mice for colitis. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Gemcitabine, Paclitaxel, Curcumin, Resveratrol, Quercetin

Safety & Interactions

No human safety data, established tolerable upper intake levels, or pharmacokinetic profiles exist for isolated euphol as a supplement. Because euphol inhibits PLA2 and modulates arachidonic acid metabolism, theoretical interactions with NSAIDs, corticosteroids, and anticoagulants such as warfarin are plausible and warrant caution. Euphorbia tirucalli latex, the primary plant source, contains co-occurring diterpene esters (e.g., phorbol esters) that are cytotoxic and irritating; purity and sourcing of any euphol extract are therefore critical safety considerations. Use during pregnancy or lactation is not recommended due to complete absence of safety data.